FDA whistleblowers accuse agency of secretly reviewing email

A group of scientists and doctors claim that FDA officials secretly monitored their email after they blew the whistle on the approval of risky medical devices. In a lawsuit, the group of 6 says the officials used the email to harass or dismiss them. And despite being warned not to expect to keep anything on their government computers under lock and key, the group claims that the FDA violated their right to privacy by reviewing personal email. Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.